

(FILE 'USPAT' ENTERED AT 18:33:36 ON 28 SEP 1998)

L1 1 S ADVANCED GLYCATION END PRODUCT
L2 16 S ADVANCED GLYCOSYLATION END PRODUCT
L3 0 S L2(P)RECEPTOR
L4 0 S L2 AND RECEPTOR
L5 8 S L2 AND ATHEROSCLEROSIS

=> d L5 1-

1. 5,356,895, Oct. 18, 1994, 1,4 piperizino inhibitors of non-enzymatic cross-linking of proteins; Peter C. Ulrich, et al., 514/255; 544/402 [IMAGE AVAILABLE]

2. 5,334,617, Aug. 2, 1994, Amino acids useful as inhibitors of the advanced glycosylation of proteins; Peter C. Ulrich, et al., 514/562, 561, 564, 567, 824, 825, 866 [IMAGE AVAILABLE]

3. 5,238,963, Aug. 24, 1993, Method and agents for inhibiting protein aging; Anthony Cerami, et al., 514/632, 866 [IMAGE AVAILABLE]

4. 5,140,048, Aug. 18, 1992, Inhibitors of nonenzymatic cross-linking; Peter C. Ulrich, et al., 514/601; 424/400, 401; 426/268, 269, 320, 321; 514/614 [IMAGE AVAILABLE]

5. 5,128,360, Jul. 7, 1992, Method and agents for inhibiting protein aging; Anthony Cerami, et al., 514/400, 632, 634, 866 [IMAGE AVAILABLE]

6. 4,983,604, Jan. 8, 1991, Inhibitors of nonenzymatic cross-linking; Peter C. Ulrich, et al., 514/238.5; 544/162 [IMAGE AVAILABLE]

7. 4,908,446, Mar. 13, 1990, Inhibitors of nonenzymatic cross-linking; Peter C. Ulrich, et al., 540/553; 544/330; 548/331.1 [IMAGE AVAILABLE]

8. 4,758,583, Jul. 19, 1988, Method and agents for inhibiting protein aging; Anthony Cerami, et al., 514/399; 435/260; 514/561, 631; 564/230 [IMAGE AVAILABLE]

US PAT NO: 5,468,777 [IMAGE AVAILABLE] L2: 1 of 16

DATE ISSUED: Nov. 21, 1995

TITLE: Method and agents for preventing and reversing the staining of teeth

INVENTOR: Dennis S. France, Morris Plains, NJ

Anthony Cerami, Shelter Island, NY

Peter C. Ulrich, Old Tappan, NJ

Laura A. Norton, Ridgewood, NJ

David L. Neer, Allendale, NJ

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

Alteon Inc., Ramsey, NJ (U.S. corp.)

APPL-NO: 08/236,228

DATE FILED: Apr. 29, 1994

ART-UNIT: 125

PRIM-EXMR: Kimberly R. Jordan

LEGAL-REP: Klauber & Jackson

US PAT NO: 5,468,777 [IMAGE AVAILABLE] L2: 1 of 16

ABSTRACT:

The present invention relates to methods and agents for preventing and reversing the staining of teeth caused by the nonenzymatic browning of proteins in the oral cavity. Suitable agents for the inhibition of nonenzymatic browning may be formulated as rinses and toothpastes, and include cysteine and cysteine derivatives. These preparations may further include known anti-plaque agents, such as chlorhexidine.

US PAT NO: 5,399,560 [IMAGE AVAILABLE] L2: 2 of 16

DATE ISSUED: Mar. 21, 1995

TITLE: 1,2,4-triazine products resulting from the inhibition of advanced glycosylation

INVENTOR: Anthony Cerami, Shelter Island, NY

Hauh-Jyun C. Chen, White Plains, NY

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

APPL-NO: 07/956,722

DATE FILED: Oct. 1, 1992

ART-UNIT: 122

PRIM-EXMR: Mukund J. Shah

ASST-EXMR: Y. N. Gupta

LEGAL-REP: Klauber & Jackson

US PAT NO: 5,399,560 [IMAGE AVAILABLE] L2: 2 of 16

ABSTRACT:

The mechanism of the inhibition of advanced glycosylation by aminoguanidine and other hydrazine type compounds was investigated using a solution of one or two molecules of aminoguanidine or other hydrazine type compound incubated with an Amadori product (1-propylamine-1-deoxy-D-fructose) under physiological conditions. This inhibition was found to proceed through the reactive intermediate 1-propylamino-1, 4-dideoxyosone to form the corresponding triazine and the dehydrazone of 1,4-dideoxyglucosone, respectively.

The triazine and dehydrazone products are useful as macrophage stimulants to activate a macrophage to effect removal of advanced glycosylation endproducts (AGEs). Additionally, they can be used in a variety of investigative methods in an effort to measure the extent of nonenzymatic glycosylation of a protein sample wherein aminoguanidine or other hydrazine-type compound is or was present during the glycosylation

process.

US PAT NO: 5,356,895 [IMAGE AVAILABLE] L2: 3 of 16
DATE ISSUED: Oct. 18, 1994
TITLE: 1,4 piperizino inhibitors of non-enzymatic cross-linking
of proteins
INVENTOR: Peter C. Ulrich, Tenafly, NJ
Anthony Cerami, Shelter Island, NY
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 07/889,141
DATE FILED: May 27, 1992
ART-UNIT: 121
PRIM-EXMR: David B. Springer
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,356,895 [IMAGE AVAILABLE] L2: 3 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises; an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. the method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,352,815 [IMAGE AVAILABLE] L2: 4 of 16
DATE ISSUED: Oct. 4, 1994
TITLE: Agent for suppression and interception of mailard reaction
INVENTOR: Norihiro Kakimoto, Tokyo, Japan
Kunie Nakamura, Kanagawa, Japan
ASSIGNEE: Asai Germanium Research Institute Co., Ltd., Tokyo, Japan
(foreign corp.)
APPL-NO: 08/031,997
DATE FILED: Mar. 16, 1993
ART-UNIT: 124
PRIM-EXMR: Jose G. Dees
ASST-EXMR: Porfirio Nazario-Gonzalez
LEGAL-REP: Burns, Doane, Swecker & Mathis

US PAT NO: 5,352,815 [IMAGE AVAILABLE] L2: 4 of 16

ABSTRACT:

The present invention provides an agent for suppression or interception of the Mailard reaction, which comprises, as the active component, an organogermanium compound represented by formula (1): ##STR1## wherein R.sub.1 to R.sub.3 may be the same or different and each of them represents a hydrogen atom, a lower alkyl group, or a phenyl group; and X represents a hydroxyl group, an O-lower alkyl group, an amino group, or a salt represented by OY (Y is a metal or a basic group-containing compound).

Said agent can effectively suppress or intercept the Mailard reaction and has high safety even when administered for a long period of time.

US PAT NO: 5,334,617 [IMAGE AVAILABLE] L2: 5 of 16
DATE ISSUED: Aug. 2, 1994
TITLE: Amino acids useful as inhibitors of the advanced
glycosylation of proteins
INVENTOR: Peter C. Ulrich, Old Tappan, NJ

ASSIGNEE: Anthony Cerami, Shelter Island, NY
The Rockefeller University, New York, NY (U.S. corp.)
Alteon Inc., Northvale, NJ (U.S. corp.)
APPL-NO: 07/825,598
DATE FILED: Jan. 27, 1992
ART-UNIT: 125
PRIM-EXMR: Frederick E. Waddell
ASST-EXMR: Kimberly R. Jordan
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,334,617 [IMAGE AVAILABLE]

L2: 5 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents are amino acids and their derivatives which contain an active nitrogen-containing group. Particular agents comprise lysine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,238,963 [IMAGE AVAILABLE] L2: 6 of 16
DATE ISSUED: Aug. 24, 1993
TITLE: Method and agents for inhibiting protein aging
INVENTOR: Anthony Cerami, Shelter Island, NY
Peter C. Ulrich, Tenafly, NJ
Michael Brownlee, New York, NY
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 07/805,200
DATE FILED: Dec. 10, 1991
ART-UNIT: 125
PRIM-EXMR: Frederick E. Waddell
ASST-EXMR: Kimberly R. Jordan
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,238,963 [IMAGE AVAILABLE]

L2: 6 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

This invention was made in part with government support under Grant Number PHS AM 19655 awarded by the National Institutes of Health. The government has certain rights in the invention.

US PAT NO: 5,140,048 [IMAGE AVAILABLE] L2: 7 of 16
DATE ISSUED: Aug. 18, 1992
TITLE: Inhibitors of nonenzymatic cross-linking
INVENTOR: Peter C. Ulrich, Tenafly, NJ
Anthony Cerami, Shelter Island, NY

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 07/605,
DATE FILED: Oct. 30, 1990
ART-UNIT: 111
PRIM-EXMR: Prince Willis, Jr.
ASST-EXMR: Jerry D. Johnson
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,140,048 [IMAGE AVAILABLE]

L2: 7 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises; an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,128,360 [IMAGE AVAILABLE] L2: 8 of 16

DATE ISSUED: Jul. 7, 1992

TITLE: Method and agents for inhibiting protein aging

INVENTOR: Anthony Cerami, Shelter Island, NY

Peter C. Ulrich, Tenafly, NJ

Michael Brownlee, New York, NY

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

APPL-NO: 07/481,869

DATE FILED: Feb. 20, 1990

ART-UNIT: 125

PRIM-EXMR: Frederick E. Waddell

ASST-EXMR: Kimberly R. Jordan

LEGAL-REP: Klauber & Jackson

US PAT NO: 5,128,360 [IMAGE AVAILABLE]

L2: 8 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 5,128,122 [IMAGE AVAILABLE] L2: 9 of 16

DATE ISSUED: Jul. 7, 1992

TITLE: Method and agents for preventing staining of teeth

INVENTOR: Anthony Cerami, Shelter Island, NY

Michael A. Yamin, Tappan, NY

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

APPL-NO: 07/604,820

DATE FILED: Oct. 26, 1990

ART-UNIT: 183

PRIM-EXMR: Ronald W. Griffin

LEGAL-REP: Klauber & Jackson

ABSTRACT:

The present invention relates to methods and agents for preventing the staining of teeth caused by the nonenzymatic browning of proteins in the oral cavity. Both oral and parenteral administration of the agents are disclosed. Suitable agents for the inhibition of nonenzymatic browning may be formulated as rinses and toothpastes, and include compounds capable of reacting with the carbonyl moiety of the early glycosylation product resulting from the initial reaction of a target protein in the nonenzymatic browning reaction. Preferred agents are those having an active nitrogen-containing substituent, as well as amino acids, their esters and amides. These preparations may further include known anti-plaque agents such as chlorhexidine.

US PAT NO: 5,126,442 [IMAGE AVAILABLE] L2: 10 of 16
DATE ISSUED: Jun. 30, 1992
TITLE: Advanced glycosylation endproducts and associated methods
INVENTOR: James G. Farmar, New York, NY
Peter Ulrich, New York, NY
Anthony Cerami, Shelter Island, NY
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 07/638,735
DATE FILED: Jan. 8, 1991
ART-UNIT: 183
PRIM-EXMR: Ronald W. Griffin
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,126,442 [IMAGE AVAILABLE] L2: 10 of 16

ABSTRACT:

New and useful chromophores have been isolated from the reaction mixture of proteins exposed to reducing sugars in the presence of sulfite over time. The chromophores are believed to be intermediates in nonenzymatic polypeptide glycosylation. The measurement of this chromophore makes possible both qualitative and quantitative assessment of the presence of nonenzymatic browning. Diagnostic and test kits are also disclosed.

US PAT NO: 5,017,696 [IMAGE AVAILABLE] L2: 11 of 16
DATE ISSUED: May 21, 1991
TITLE: Advanced glycosylation end products and associated methods
INVENTOR: James G. Farmar, New York, NY
Peter Ulrich, New York, NY
Anthony Cerami, Shelter Island, NY
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 07/453,935
DATE FILED: Dec. 20, 1989
ART-UNIT: 183
PRIM-EXMR: Ronald W. Griffin
LEGAL-REP: Klauber & Jackson

US PAT NO: 5,017,696 [IMAGE AVAILABLE] L2: 11 of 16

ABSTRACT:

New and useful chromophores have been isolated from the reaction mixture of proteins exposed to reducing sugars in the presence of sulfite over time. The chromophores are believed to be intermediates in nonenzymatic polypeptide glycosylation. The measurement of this chromophore makes possible both qualitative and quantitative assessment of the presence of nonenzymatic browning. Diagnostic and test kits are also disclosed.

US PAT NO: 4,983,604 [IMAGE AVAILABLE] L2: 12 of 16

DATE ISSUED: Jan. 8, 1991
TITLE: Inhibitors of nonenzymatic cross-linking
INVENTOR: Peter C. Ulrich, New York, NY
Anthony Cerami, Shelter Island, NY
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 07/264,930
DATE FILED: Nov. 2, 1988
ART-UNIT: 117
PRIM-EXMR: O. Chaudhuri
ASST-EXMR: Jerry D. Johnson
LEGAL-REP: Klauber & Jackson

US PAT NO: 4,983,604 [IMAGE AVAILABLE]

L2: 12 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 4,908,446 [IMAGE AVAILABLE] L2: 13 of 16
DATE ISSUED: Mar. 13, 1990
TITLE: Inhibitors of nonenzymatic cross-linking
INVENTOR: Peter C. Ulrich, New York, NY
Anthony Cerami, Shelter Island, NY
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 07/119,958
DATE FILED: Nov. 13, 1987
ART-UNIT: 118
PRIM-EXMR: William R. Dixon, Jr.
ASST-EXMR: Jerry D. Johnson
LEGAL-REP: Klauber & Jackson

US PAT NO: 4,908,446 [IMAGE AVAILABLE]

L2: 13 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents contain an active nitrogen-containing group, such as a hydrazine group. Particular agents comprise aminoguanidine derivatives. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 4,761,368 [IMAGE AVAILABLE] L2: 14 of 16
DATE ISSUED: Aug. 2, 1988
TITLE: Method and agents for measuring protein aging
INVENTOR: Anthony Cerami, Flanders, NJ
ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)
APPL-NO: 06/885,967
DATE FILED: Jul. 15, 1986
ART-UNIT: 128
PRIM-EXMR: Sidney Marantz

ASST-EXMR: Richard Wagner
LEGAL-REP: Klaube Jackson

US PAT NO: 4,761,368 [IMAGE AVAILABLE]

L2: 14 of 16

ABSTRACT:

A new and useful fluorescent chromophore has been isolated and identified which has been observed in proteins exposed to glucose over time, and whose fluorescent properties closely resemble those of the polypeptide after it undergoes advanced glycosylation. The chromophore has been structurally identified and named 2-furoyl-4(5)-(2-furanyl)-1H-imidazole, and is believed to be one of the end products of extended nonenzymatic polypeptide glycosylation, which results in the state known as nonenzymatic browning (NEB). The measurement of this chromophore makes possible both qualitative and quantitative assessment of the degree of aging. Diagnostic and test kits are also disclosed.

US PAT NO: 4,758,583 [IMAGE AVAILABLE]

L2: 15 of 16

DATE ISSUED: Jul. 19, 1988

TITLE: Method and agents for inhibiting protein aging

INVENTOR: Anthony Cerami, Flanders, NJ
Peter C. Ulrich, New York, NY
Michael Brownlee, New York, NY

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

APPL-NO: 06/798,032

DATE FILED: Nov. 14, 1985

ART-UNIT: 125

PRIM-EXMR: Stanley J. Friedman

LEGAL-REP: David A. Jackson, Richard M. Goldberg, Barbara L. Renda

US PAT NO: 4,758,583 [IMAGE AVAILABLE]

L2: 15 of 16

ABSTRACT:

The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents may contain an active nitrogen-containing group, such as a hydrazine group, and may further be at least partially derived from amino acids. Particular agents comprise aminoguanidine, .alpha.-hydrazinohistidine and lysine. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

US PAT NO: 4,665,192 [IMAGE AVAILABLE]

L2: 16 of 16

DATE ISSUED: May 12, 1987

TITLE: 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole

INVENTOR: Anthony Cerami, Flanders, NJ

ASSIGNEE: The Rockefeller University, New York, NY (U.S. corp.)

APPL-NO: 06/590,820

DATE FILED: Mar. 19, 1984

ART-UNIT: 121

PRIM-EXMR: Richard A. Schwartz

LEGAL-REP: David A. Jackson

US PAT NO: 4,665,192 [IMAGE AVAILABLE]

L2: 16 of 16

ABSTRACT:

A new and useful fluorescent chromophore has been isolated and identified which has been observed in proteins exposed to glucose over time, and whose fluorescent properties closely resemble those of the polypeptide

after it undergoes advanced glycosylation. The chromophore has been structurally identified and named 2-(2-furoyl)-4(5)-2(furoyl)-1H-imidazole, and is believed to be one of the end products of extended nonenzymatic polypeptide glycosylation, which results in the state known as nonenzymatic browning (NEB). The measurement of this chromophore makes possible both qualitative and quantitative assessment of the degree of aging. Diagnostic and test kits are also disclosed.

medline, CAPUS, WPIJS

9/28/98

=> s advanced glycation end product

L1 202 ADVANCED GLYCATION END PRODUCT

=> s advanced glycosylation end product

L2 387 ADVANCED GLYCOSYLATION END PRODUCT

=> s l1 or l2

L3 534 L1 OR L2

=> s L3 and receptor

L4 196 L3 AND RECEPTOR

=> s l4 and vascular

L5 71 L4 AND VASCULAR

=> s l4 and atherosclerosis

L6 40 L4 AND ATHEROSCLEROSIS

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 34 DUP REM L6 (6 DUPLICATES REMOVED)

YOU HAVE REQUESTED DATA FROM 34 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 34 MEDLINE DUPLICATE 1
AN 1998202099 MEDLINE
DN 98202099
TI Advanced glycosylation end products induced tissue factor expression
in human monocyte-like U937 cells and increased tissue factor
expression in monocytes from diabetic patients.
AU Ichikawa K; Yoshinari M; Iwase M; Wakisaka M; Doi Y; Iino K;
Yamamoto M; Fujishima M
CS Second Department of Internal Medicine, Faculty of Medicine, Kyushu
University, Fukuoka, Japan.
SO ATHEROSCLEROSIS, (1998 Feb) 136 (2) 281-7.
Journal code: 95X. ISSN: 0021-9150.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199807
EW 19980705

L7 ANSWER 2 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1998:116256 CAPLUS
DN 128:152392
TI Biological significance of glycation
AU Nagai, Ryoji; Sano, Hiroyuki; Horiuchi, Seikoh
CS Sch. Med., Kumamoto Univ., Kumamoto, 860, Japan
SO Kagaku to Seibutsu (1998), 36(2), 83-88
CODEN: KASEAA; ISSN: 0453-073X
PB Gakkai Shuppan Senta
DT Journal; General Review
LA Japanese

L7 ANSWER 3 OF 34 CAPLUS COPYRIGHT 1998 ACS DUPLICATE 2
AN 1997:696868 CAPLUS
DN 128:2908
TI Antibodies against the **advanced glycosylation
end-product receptor** and uses thereof
IN Morser, Michael John; Nagashima, Mariko; Hollander, Doris Anne
PA Schering Aktiengesellschaft Patente, Germany
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
PI WO 9739125 A1 19971023
DS W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG

AI WO 97-EP1834 19970411
PRAI US 96-633148 19960416
DT Patent
LA English

L7 ANSWER 4 OF 34 CAPLUS COPYRIGHT 1998 ACS DUPLICATE 3
AN 1997:696864 CAPLUS
DN 128:10317

TI **Advanced glycosylation end-product receptor** provides and their uses for increasing vascular permeability in disease conditions
IN Morser, Michael John; Nagashima, Mariko
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
PI WO 9739121 A1 19971023
DS W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 97-EP1832 19970411
PRAI US 96-633147 19960416
DT Patent
LA English

L7 ANSWER 5 OF 34 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
AN 97-393374 [36] WPIDS
DNC C97-126340
TI Inhibiting damage to cells in e.g. Alzheimer's disease - using an agent which inhibits interaction of an amyloid-beta peptide with a **receptor for advanced glycosylation end product.**
DC B04 D16
IN SCHMIDT, A M; STERN, D; YAN, S D
PA (UYCO) UNIV COLUMBIA NEW YORK
CYC 21
PI WO 9726913 A1 970731 (9736)* EN 91 pp A61K039-395
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU CA JP MX
AU 9718327 A 970820 (9749) A61K039-395
ADT WO 9726913 A1 WO 97-US857 970121; AU 9718327 A AU 97-18327 970121
FDT AU 9718327 A Based on WO 9726913
PRAI US 96-592070 960126
IC ICM A61K039-395
ICS A61K038-00; C07K016-00

L7 ANSWER 6 OF 34 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
AN 98-062326 [06] WPIDS
CR 85-249222 [40]; 87-137378 [20]; 90-098908 [13]; 92-131583 [16]; 92-159422 [19]; 92-192216 [23]; 92-249455 [30]; 92-258953 [31]; 92-258959 [31]; 93-213460 [26]; 93-258353 [32]; 93-280695 [35]; 93-295311 [37]; 93-345003 [43]; 93-377384 [47]; 93-413441 [51]; 94-182638 [22]; 94-217082 [26]; 94-302650 [37]; 94-332366 [41]; 94-341036 [42]; 96-048998 [05]; 96-086502 [09]; 96-320533 [32]; 98-229760 [20]; 98-229866 [20]
DNN N98-049080 DNC C98-021692
TI Estimation of lipid oxidation in vivo - by assay for AGE-lipid(s), useful for monitoring and diagnosing vascular disease.
DC B04 D16 S03
IN BUCALA, R J; CERAMI, A; TRACEY, K J; VLASSARA, H
PA (PICO-N) PICOWER INST MEDICAL RES
CYC 1
PI US 5700447 A 971223 (9806)* 37 pp G01N033-48
ADT US 5700447 A CIP of US 92-887279 920521, CIP of US 93-29417 930311, US 94-319747 941007
PRAI US 94-319747 941007; US 92-887279 920521; US 93-29417 930311
IC ICM G01N033-48

L7 ANSWER 7 OF 34 MEDLINE DUPLICATE 4
AN 1998012750 MEDLINE
DN 98012750

TI Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of **atherosclerosis** in LDL **receptor**-deficient mice.

AU Reaven P; Merat S; Casanada F; Sutphin M; Palinski W

CS Department of Medicine, University of California, San Diego, La Jolla, 92093-0682, USA.

NC HL-14197 (NHLBI)

SO ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, (1997 Oct) 17 (10) 2250-6.

Journal code: B89. ISSN: 1079-5642.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199801

EW 19980104

L7 ANSWER 8 OF 34 MEDLINE DUPLICATE 5

AN 97465000 MEDLINE

DN 97465000

TI Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with **atherosclerosis**: relationship to tissue AGEs.

AU Stitt A W; He C; Friedman S; Scher L; Rossi P; Ong L; Founds H; Li Y M; Bucala R; Vlassara H

CS Picower Institute for Medical Research, Manhasset, New York, USA.

NC AG09453 (NIA)

AG06943 (NIA)

SO MOLECULAR MEDICINE, (1997 Sep) 3 (9) 617-27.

Journal code: CG3. ISSN: 1076-1551.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199801

EW 19980104

L7 ANSWER 9 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1997:146011 CAPLUS

DN 126:249779

TI The **receptor** for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells

AU Higashi, Takayuki; Sano, Hiroyuki; Saishoji, Tewtsushi; Ikeda, Kazuyoshi; Jinnouchi, Yoshiteru; Kanzaki, Tetsuto; Morisaki, Nobuhiro; Rauvala, Heikki; Shichiri, Motoaki; Horiuchi, Seikoh

CS Departments Biochemistry and Metabolic Medicine, Kumamoto Univ. School Medicine, Kumamoto, 860, Japan

SO Diabetes (1997), 46(3), 463-472

CODEN: DIAEAZ; ISSN: 0012-1797

PB American Diabetes Association, Inc.

DT Journal

LA English

L7 ANSWER 10 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1997:249716 CAPLUS

DN 126:315557

TI What's the RAGE? The **receptor** for advanced glycation end products (RAGE) and the dark side of glucose

AU Yan, S. D.; Stern, D.; Schmidt, A. M.

CS Departments of Pathology, Surgery, Physiology and Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, 10032, USA

SO Eur. J. Clin. Invest. (1997), 27(3), 179-181

CODEN: EJCIB8; ISSN: 0014-2972

PB Blackwell

DT Journal; General Review
LA English

L7 ANSWER 11 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1997:437490 CAPLUS
DN 127:107242
TI Atherogenesis and advanced glycation: promotion, progression, and prevention
AU Stitt, Alan W.; Bucala, Richard; Vlassara, Helen
CS The Picower Institute for Medical Research, Manhasset, NY, 11030, USA
SO Ann. N. Y. Acad. Sci. (1997), 811(Atherosclerosis IV: Recent Advances in Atherosclerosis Research), 115-129
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal; General Review
LA English

L7 ANSWER 12 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1997:180263 CAPLUS
DN 126:223591
TI Advanced glycation end products, oxidant stress and vascular lesions
AU Chappey, O.; Dosquet, C.; Wautier, M-P.; Wautier, J-L.
CS Biologie Vasculaire et Cellulaire, Immunohematologie, Pariss, Fr.
SO Eur. J. Clin. Invest. (1997), 27(2), 97-108
CODEN: EJCIB8; ISSN: 0014-2972
PB Blackwell
DT Journal; General Review
LA English

L7 ANSWER 13 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1998:311203 CAPLUS
DN 129:107222
TI Advanced glycosylation: role in **atherosclerosis**
AU Bucala, Richard
CS The Picower Institute for Medical Research, Manhasset, NY, USA
SO Glycation Hypothesis Atheroscler. (1997), 89-107. Editor(s): Colaco, Camilo A. L. S. Publisher: Landes Bioscience, Austin, Tex.
CODEN: 66AXAH
DT Conference; General Review
LA English

L7 ANSWER 14 OF 34 MEDLINE
AN 97429856 MEDLINE
DN 97429856
TI Recent progress in advanced glycation end products and diabetic complications.
AU Vlassara H
CS Picower Institute for Medical Research, Manhasset, New York 11030, USA.
SO DIABETES, (1997 Sep) 46 Suppl 2 S19-25.
Journal code: E8X. ISSN: 0012-1797.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199711
EW 19971104

L7 ANSWER 15 OF 34 MEDLINE
AN 96325216 MEDLINE
DN 96325216
TI Receptors for advance glycation end-products (AGE) - expression by endothelial cells in non-diabetic uraemic patients.
AU Greten J; Kreis I; Wiesel K; Stier E; Schmidt A M; Stern D M; Ritz E; Waldherr R; Nawroth P P

CS Department of Medicine, University of Heidelberg, Germany.
 SO NEPHROLOGY, DIALYSIS, TRANSPLANTATION, (1996 May) 11(5) 786-90.
 Journal code: N7J. ISSN: 0931-0509.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199612

L7 ANSWER 16 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1996:532565 CAPLUS
 DN 125:192089
 TI Advanced glycation end products (AGE)-modified proteins and their potential relevance to **atherosclerosis**
 AU Horiuchi, Seikoh
 CS School Medicine, Kumamoto University, Kumamoto, 860, Japan
 SO Trends Cardiovasc. Med. (1996), 6(5), 163-168
 CODEN: TCMDEQ; ISSN: 1050-1738
 DT Journal; General Review
 LA English

L7 ANSWER 17 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1996:604824 CAPLUS
 DN 125:324992
 TI Pathophysiological role of AGE in **atherosclerosis**
 AU Higashi, Takayuki; Kume, Shuichi; Ikeda, Kazuyoshi; Saishoji, Tetsushi; Sano, Hiroyuki; Jinnouchi, Yoshiteru; Nagai, Ryoji; Takahashi, Kiyoshi; Shichiri, Motoaki; Horiuchi, Seikoh
 CS Sch. Med., Kumamoto Univ., Kumamoto, 860, Japan
 SO Domyaku Koka (1996), 24(3), 89-95
 CODEN: DOMKDM; ISSN: 0386-2682
 DT Journal
 LA Japanese

L7 ANSWER 18 OF 34 MEDLINE
 AN 97197254 MEDLINE
 DN 97197254
 TI Extra- and intracellular localization of advanced glycation end-products in human atherosclerotic lesions.
 AU Horiuchi S; Sano H; Higashi T; Ikeda K; Jinnouchi Y; Nagai R; Takahashi K
 CS Departments of Biochemistry, Kumamoto University School of Medicine, Japan.
 SO NEPHROLOGY, DIALYSIS, TRANSPLANTATION, (1996) 11 Suppl 5 81-6. Ref: 36
 Journal code: N7J. ISSN: 0931-0509.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals
 EM 199708
 EW 19970801

L7 ANSWER 19 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1996:560126 CAPLUS
 DN 125:272538
 TI Elucidation of the significance of advanced glycation end products (AGE) of Maillard reaction in diabetic complications and diseases based on aging
 AU Araki, Norie; Shiga, Masanobu; Sakamoto, Tamami
 CS Sch. Med., Kumamoto Univ., Kumamoto, 860, Japan
 SO Sagawa Sentan Kagaku Gijutsu Shinko Zaidan Josei Kenkyu Hokokusho (1996), Volume Date 1995, 8th, 52-57
 CODEN: SSKHFS; ISSN: 0919-0414

DT Journal
LA Japanese

L7 ANSWER 20 OF 34 MEDLINE
AN 95386695 MEDLINE
DN 95386695
TI Advanced glycation endproducts interacting with their endothelial **receptor** induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.
AU Schmidt A M; Hori O; Chen J X; Li J F; Crandall J; Zhang J; Cao R; Yan S D; Brett J; Stern D
CS Department of Medicine, Columbia University-College of Physicians and Surgeons, New York, New York 10032, USA..
NC AG-00602 (NIA)
HL-21006 (NHLBI)
HL-42833 (NHLBI)
+
SO JOURNAL OF CLINICAL INVESTIGATION, (1995 Sep) 96 (3) 1395-403.
Journal code: HS7. ISSN: 0021-9738.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
EM 199512

L7 ANSWER 21 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1995:615403 CAPLUS
DN 123:80729
TI Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits
AU Palinski, Wulf; Koschinsky, Theodor; Butler, Susan W.; Miller, Elizabeth; Vlassara, Helen; Cerami, Anthony; Witztum, Joseph L.
CS Department of Medicine, University of California, San Diego, La Jolla, CA, USA
SO Arterioscler., Thromb., Vasc. Biol. (1995), 15(5), 571-82
CODEN: ATVBFA; ISSN: 1079-5642
DT Journal
LA English

L7 ANSWER 22 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1995:630906 CAPLUS
DN 123:80800
TI Macrophage scavenger **receptor** mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction
AU Araki, Norie; Higashi, Takayuki; Mori, Takashi; Shibayama, Rie; Kawabe, Yoshiki; Kodama, Tatsuhiko; Takahashi, Kiyoshi; Schichiri, Motoaki; Horiuchi, Seikoh
CS Department of Biochemistry, Kumamoto University School of Medicine, Kumamoto, 860, Japan
SO Eur. J. Biochem. (1995), 230(2), 408-15
CODEN: EJBCAI; ISSN: 0014-2956
DT Journal
LA English

L7 ANSWER 23 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1996:93551 CAPLUS
DN 124:171917
TI Receptors for advanced glycation endproducts: in vivo role and human studies
AU Vlassara, Helen
CS Picower Institute Medical Research, Manhasset, NY, 11030, USA
SO Int. Congr. Ser. (1995), 1100(Diabetes 1994), 286-91
CODEN: EXMDA4; ISSN: 0531-5131
DT Journal; General Review

LA English

L7 ANSWER 24 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1995:844467 CAPLUS
 DN 124:6213
 TI Structures of advanced glycation end products and their role in pathophysiological states
 AU Horiuchi, Seikoh; Higashi, Takayuki; Ikeda, Kazuyoshi; Saishoji, Tetsushi; Jinnouchi, Yoshiteru; Sano, Hiroyuki; Araki, Norie
 CS School Medicine, Kumamoto University, Kumamoto, Japan
 SO Contrib. Nephrol. (1995), 112(Dialysis-Related Amyloidosis), 32-41
 CODEN: CNEPDD; ISSN: 0302-5144
 DT Journal
 LA English

L7 ANSWER 25 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1994:676201 CAPLUS
 DN 121:276201
 TI Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
 IN Bucala, Richard J.; Vlassara, Helen; Cerami, Anthony
 PA Picower Institute for Medical Research, USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 PI WO 9420083 A1 19940915
 DS W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN
 RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
 AI WO 93-US10880 19931112
 PRAI US 93-29417 19930311
 DT Patent
 LA English
 OS MARPAT 121:276201

L7 ANSWER 26 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1994:627858 CAPLUS
 DN 121:227858
 TI Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency
 AU Bucala, Richard; Makita, Zenji; Vega, Gloria; Grundy, Scott; Roschinsky, Theodor; Cerami, Anthony; Vlassara, Helen
 CS The Picower Institute for Medical Research, Manhasset, NY, 11030, USA
 SO Proc. Natl. Acad. Sci. U. S. A. (1994), 91(20), 9441-5
 CODEN: PNASA6; ISSN: 0027-8424
 DT Journal
 LA English

L7 ANSWER 27 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1994:698026 CAPLUS
 DN 121:298026
 TI Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
 AU Schmidt, Ann Marie; Hori, Osamu; Brett, Jerold; Yan, Shi Du; Wautier, Jean-Luc; Stern, David
 CS College of Physicians and Surgeons, Columbia University, New York, NY, 10032, USA
 SO Arterioscler. Thromb. (1994), 14(10), 1521-8
 CODEN: ARTTE5; ISSN: 1049-8834
 DT Journal; General Review
 LA English

L7 ANSWER 28 OF 34 CAPLUS COPYRIGHT 1998 ACS

AN 1995:278135 CAPLUS
 DN 122:233401
 TI AGE-receptors and in vivo biological effects of AGEs
 AU Vlassara, Helen
 CS The Picower Institute for Medical Research, Manhasset/New York,
 11030, USA
 SO Spec. Publ. - R. Soc. Chem. (1994), 151(Maillard Reactions in
 Chemistry, Food, and Health), 254-61
 CODEN: SROCDO; ISSN: 0260-6291
 DT Journal; General Review
 LA English

L7 ANSWER 29 OF 34 MEDLINE
 AN 94017190 MEDLINE
 DN 94017190
 TI Carbohydrate metabolism.
 AU Iguchi A; Miura H; Sakamoto N
 CS Department of Geriatric Medicine, Nagoya Univ. Sch. of Med..
 SO NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE, (1993 Aug) 51
 (8) 1961-6.
 Journal code: KIM. ISSN: 0047-1852.
 CY Japan
 DT Journal; Article; (JOURNAL ARTICLE)
 LA Japanese
 EM 199401

L7 ANSWER 30 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1994:240942 CAPLUS
 DN 120:240942
 TI Survey of the distribution of a newly characterized **receptor**
 for advanced glycation end products in tissues
 AU Brett, Jerold; Schmidt, Ann Marie; Yan, Shi Du; Zou, Yu Shan;
 Weidman, Elliott; Pinsky, David; Nowygrod, Roman; Neeper, Michael;
 Przysiecki, Craig; et al.
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
 SO Am. J. Pathol. (1993), 143(6), 1699-712
 CODEN: AJPAA4; ISSN: 0002-9440
 DT Journal
 LA English

L7 ANSWER 31 OF 34 CAPLUS COPYRIGHT 1998 ACS
 AN 1993:405414 CAPLUS
 DN 119:5414
 TI Monocyte/macrophage receptors for proteins modified by advanced
 glycation end products: Role in normal tissue remodeling and in
 pathology
 AU Vlassara, H.
 CS Lab. Med. Biochem., Rockefeller Univ., New York, NY, 10021-6399, USA
 SO Mononucleated Phagocytes (1992), 193-201. Editor(s): Van Furth, Ralph.
 Publisher: Kluwer, Dordrecht, Neth.
 CODEN: 59AEA4
 DT Conference; General Review
 LA English

L7 ANSWER 32 OF 34 MEDLINE DUPLICATE 6
 AN 92128692 MEDLINE
 DN 92128692
 TI Chromatographic quantitation of plasma and erythrocyte pentosidine
 in diabetic and uremic subjects.
 AU Odetti P; Fogarty J; Sell D R; Monnier V M
 CS Institute of Pathology, Case Western Reserve University, Cleveland,
 Ohio 44106..
 NC AG 05601 (NIA)
 EY 07099 (NEI)
 SO DIABETES, (1992 Feb) 41 (2) 153-9.
 Journal code: E8X. ISSN: 0012-1797.

CY United States
DT Journal; Article (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199205

L7 ANSWER 33 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1992:405301 CAPLUS
DN 117:5301
TI Secretion of a chemotactic substance(s) by AGE-stimulated human monocytes
AU Gilcrease, Michael Z.; Hoover, Richard L.
CS Dep. Pathol., Vanderbilt Univ., Nashville, TN, 37232, USA
SO Diabetes Res. Clin. Pract. (1992), 16(1), 7-11
CODEN: DRCPE9; ISSN: 0168-8227
DT Journal
LA English

L7 ANSWER 34 OF 34 CAPLUS COPYRIGHT 1998 ACS
AN 1990:530471 CAPLUS
DN 113:130471
TI Activated human monocytes exhibit **receptor**-mediated adhesion to a non-enzymically glycosylated protein substrate
AU Gilcrease, M. Z.; Hoover, R. L.
CS Dep. Pathol., Vanderbilt Univ., Nashville, TN, 37232, USA
SO Diabetologia (1990), 33(6), 329-33
CODEN: DBTG AJ; ISSN: 0012-186X
DT Journal
LA English